Re-personalization and stratification of hemophilia care in an evolving treatment landscape

References

• Collins PW, Blanchette VS, Fischer K, et al. Ewenstein B; rAHF-PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009 Mar;7(3):413–420. doi: 10.1111/j.1538-7836.2008.03270.x
   PubMed Web of Science ®Google Scholar
• Iorio A, Edginton AN, Blanchette V, et al. Performing and interpreting individual pharmacokinetic profiles in patients with hemophilia A or B: Rationale and general considerations. Res Pract Thromb Haemost. 2018 May 20;2(3):535–548. doi: 10.1002/rth2.12106
   PubMed Web of Science ®Google Scholar
• Ragni MV, Croteau SE, Morfini M, et al. Subcommittee on factor VIII, factor IX, and rare bleeding disorders. Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH. J Thromb Haemost. 2018 Jul;16(7):1437–1441. doi: 10.1111/jth.14153
   PubMed Web of Science ®Google Scholar
• Valentino LA, Mamonov V, Hellmann A, et al. Prophylaxis Study Group. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost. 2012 Mar;10(3):359–367. doi: 10.1111/j.1538-7836.2011.04611.x
   PubMed Web of Science ®Google Scholar
• Lissitchkov T, Rusen L, Georgiev P, et al. PK-guided personalized prophylaxis with Nuwiq® (human-cl rhFVIII) in adults with severe haemophilia A. Haemophilia. 2017 Sep;23(5):697–704. doi: 10.1111/hae.13251
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007 Aug 9;357(6):535–544. doi: 10.1056/NEJMoa067659
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Kempton CL, Reding MT, et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost. 2013 Jun;11(6):1119–1127. Erratum in: J Thromb Haemost. 2014 Jan;12. doi: 10.1111/jth.12202
   PubMed Web of Science ®Google Scholar
• Schwaab R, Brackmann HH, Meyer C, et al. Oldenburg J Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost. 1995 Dec;74(6):1402–1406. doi: 10.1055/s-0038-1649954
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med. 2016 May 26;374(21):2054–2064. doi: 10.1056/NEJMoa1516437
   PubMed Web of Science ®Google Scholar
• Spena S, Garagiola I, Cannavò A, et al. Peyvandi F; SIPPET Study Group Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement. J Thromb Haemost. 2018 Apr;16(4):778–790. doi: 10.1111/jth.13961
   PubMed Web of Science ®Google Scholar
• Whelan SF, Hofbauer CJ, Horling FM, et al. Reipert BM Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood. 2013 Feb 7;121(6):1039–1048. doi: 10.1182/blood-2012-07-444877
   PubMed Web of Science ®Google Scholar
• Astermark J, Oldenburg J, Pavlova A, et al. MIBS study Group. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood. 2006 Apr 15;107(8):3167–3172. doi: 10.1182/blood-2005-09-3918
   PubMed Web of Science ®Google Scholar
• Astermark J, Oldenburg J, Carlson J, et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood. 2006 Dec 1;108(12):3739–3745. doi: 10.1182/blood-2006-05-024711
   PubMed Web of Science ®Google Scholar
• Pavlova A, Delev D, Lacroix-Desmazes S, et al. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J Thromb Haemost. 2009 Dec;7(12):2006–2015. doi: 10.1111/j.1538-7836.2009.03636.x
   PubMed Web of Science ®Google Scholar
• Astermark J, Donfield SM, Gomperts ED, et al. Berntorp E; Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Blood. 2013 Feb 21;121(8):1446–1454. doi: 10.1182/blood-2012-06-434803
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017 Aug 31;377(9):809–818. doi: 10.1056/NEJMoa1703068
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med. 2017 Aug 31;377(9):819–828. doi: 10.1056/NEJMoa1616569
   PubMed Web of Science ®Google Scholar
• Chowdary P, Lethagen S, Friedrich U, et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015 May;13(5):743–754. doi: 10.1111/jth.12864
   PubMed Web of Science ®Google Scholar
• Callaghan MU, Sidonio R, Pipe SW. Novel therapeutics for hemophilia and other bleeding disorders. Blood. 2018 Jul 5;132(1):23–30. doi: 10.1182/blood-2017-09-743385
   PubMed Web of Science ®Google Scholar
• Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl. 1965;36(Suppl 77):3–132. doi: 10.3109/ort.1965.36.suppl-77.01
   Google Scholar
• Nilsson IM, Hedner U, Ahlberg A. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand. 1976 Mar;65(2):129–135. doi: 10.1111/j.1651-2227.1976.tb16525.x
   PubMed Web of Science ®Google Scholar
• Den Uijl IE, Mauser Bunschoten EP, Roosendaal G, et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia. 2011 Nov;17(6):849–853. doi: 10.1111/j.1365-2516.2011.02539.x
   PubMed Web of Science ®Google Scholar
• Soucie JM, Monahan PE, Kulkarni R, et al. US hemophilia Treatment Center Network. The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B. Blood Adv. 2018 Aug 28;2(16):2136–2144. doi: 10.1182/bloodadvances.2018020552
   PubMed Web of Science ®Google Scholar
• Leissinger C, Gringeri A, Antmen B, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med. 2011 Nov 3;365(18):1684–1692. Erratum in: N Engl J Med. 2011 Dec 22;365. doi: 10.1056/NEJMoa1104435
   PubMed Web of Science ®Google Scholar
• Collins PW, Liesner R, Makris M, et al. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. Haemophilia. 2018 May;24(3):344–347. doi: 10.1111/hae.13495
   PubMed Web of Science ®Google Scholar
• Batty P, Austin SK, Khair K, et al. Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A. Br J Haematol. 2017 Mar;176(5):796–804. doi: 10.1111/bjh.14543
   PubMed Web of Science ®Google Scholar
• Aledort LM, Ewenstein BM. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017 Nov 30;377(22):2193. doi: 10.1056/NEJMc1712683
   PubMed Web of Science ®Google Scholar
• Aledort LM. The evolution of comprehensive haemophilia care in the United States: perspectives from the frontline. Haemophilia. 2016 Sep;22(5):676–683. doi: 10.1111/hae.12970
   PubMed Web of Science ®Google Scholar
• Chalmers EA, Alamelu J, Collins PW, et al. Paediatric & Rare Disorders Working Parties of the UK haemophilia Doctors Organization. intracranial haemorrhage in children with inherited bleeding disorders in the UK 2003-2015: A national cohort study. Haemophilia. 2018 Jul;24(4):641–647. doi: 10.1111/hae.13461
   PubMed Web of Science ®Google Scholar
• Collins PW, Chalmers E, Hart DP, et al. UK haemophilia Centre Doctors. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. Br J Haematol. 2013 Jan;160(2):153–170. doi: 10.1111/bjh.12091
   PubMed Web of Science ®Google Scholar
• Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost. 2017 Jun 28;117(7):1348–1357. doi: 10.1160/TH17-01-0030
   PubMed Web of Science ®Google Scholar
• Uchida N, Sambe T, Yoneyama K, et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood. 2016 Mar 31;127(13):1633–1641. 1. doi: 10.1182/blood-2015-06-650226
   PubMed Web of Science ®Google Scholar
• Gouw SC, van den Berg HM, Fischer K, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013;121(20):4046-4055.
   Google Scholar
• Rangarajan S, Walsh L, Lester W, et al. AAV5-factor VIII gene transfer in severe hemophilia A. N Engl J Med. 2017 Dec 28;377(26):2519–2530. doi: 10.1056/NEJMoa1708483
   PubMed Web of Science ®Google Scholar
• George LA, Sullivan SK, Giermasz A, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017 Dec 7;377(23):2215–2227. doi: 10.1056/NEJMoa1708538
   PubMed Web of Science ®Google Scholar
• Hay CR, DiMichele DM. International immune tolerance study. The principal results of the international immune tolerance study: a randomized dose comparison. Blood. 2012 Feb 9;119(6):1335–1344. doi: 10.1182/blood-2011-08-369132
   PubMed Web of Science ®Google Scholar